On October 8, 2026, Barclays upgraded DexCom to strong-buy. Analysts have a consensus Buy rating on the company, with a consensus price target of $91.96.
Citi reaffirmed DexCom as one of its top two picks in medical technology. The bank cited operational improvements, including revenue growth, margin expansion, and market-share gains in continuous glucose monitoring (CGM).
Separately, reports said HWG Holdings LP acquired more than 96,000 DexCom shares in the third quarter. The stake was valued at approximately $8.3 million.